-
AI gobbling up memory chips essential to gadget makers
-
'One Battle After Another' leads the charge for Golden Globes
-
Kyrgios to play doubles only at Australian Open
-
Firefighters warn of 'hectic' Australian bushfires
-
International Space Station crew to return early after astronaut medical issue
-
Arsenal in 'strong position' despite missed opportunity for Arteta
-
US House revolt advances Obamacare subsidy extension
-
Swiss mining giant Glencore in merger talks with Rio Tinto
-
US snowboard star Kim dislocates shoulder ahead of Olympic three-peat bid
-
Brazil's Lula vetoes bill reducing Bolsonaro's sentence
-
AC Milan scrape a point with Genoa after late penalty howler
-
Arsenal miss chance to stretch lead in Liverpool stalemate
-
Stocks mixed as traders await US jobs data, oil rebounds
-
After Minneapolis shooting, AI fabrications of victim and shooter
-
Trump says no pardon for Sean 'Diddy' Combs
-
Venezuela begins 'large' prisoner release amid US pressure
-
Real Madrid beat Atletico to set up Clasico Spanish Super Cup final
-
Heavy wind, rain, snow batters Europe
-
PSG beat Marseille on penalties to win French Champions Trophy
-
From sci-fi to sidewalk: exoskeletons go mainstream
-
Rare genius dogs learn vocabulary by eavesdropping: study
-
EU orders Musk's Grok AI to keep data after nudes outcry
-
Venezuela announces release of 'large number' of prisoners
-
Rare gorilla twins born in conflict-hit DR Congo nature park
-
Dolphins fire head coach McDaniel after four seasons
-
Three ships head to US with Venezuela oil as capacity concerns grow
-
Trump says US could run Venezuela and its oil for years
-
Heavy wind, rain, snow to batter Europe
-
Morocco coach Regragui aims to shift pressure to Cameroon before AFCON clash
-
HRW warns right to protest 'under attack' in UK
-
French farmers rage against EU-Mercosur trade deal
-
Humanoid robots go for knockout in high-tech Vegas fight night
-
Brazil's Lula vetoes law reducing Bolsonaro's sentence
-
Macron accuses US of 'turning away' from allies, breaking rules
-
Joshua pays tribute to close friends killed in crash
-
Protesters, US law enforcement clash after immigration officer kills woman
-
French ex-spy chief cops suspended jail term for 15 mn euro shakedown
-
Syria bombs Kurdish areas in city of Aleppo
-
Confusion reigns over Venezuela's oil industry as US looms
-
Stocks retrench as traders eye geopolitics, US jobs data
-
US trade gap shrinks to smallest since 2009 as imports fall
-
Russia releases French researcher in prisoner exchange
-
Spain signs agreement with Church to compensate abuse victims
-
Macron accuses US of 'breaking free from international rules'
-
US could run Venezuela, tap its oil for years, Trump says
-
England to stick with Stokes and McCullum despite Ashes flop
-
Nobel laureate Bialiatski tells AFP 'important' to keep pressure on Belarus
-
Russia slams Western peacekeeping plan for Ukraine
-
Bordeaux's Du Preez wary of Northampton's Champions Cup revenge mission
-
Romero apologises for Spurs slump as crisis deepens
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
O.Norris--AMWN